Ful-23

Ful-23 is a novel small molecule inhibitor of Monocarboxylate Transporter 4 (MCT4) being investigated for the treatment of acute myeloid leukemia (AML). Developed by researchers at Charles Drew University of Medicine & Science, Ful-23 targets the metabolic vulnerabilities of cancer cells by blocking the export of lactate, leading to intracellular lactate accumulation and acidification. This metabolic disruption results in inhibited cell proliferation and the induction of apoptosis. Preclinical studies have demonstrated that Ful-23 exhibits significant synergistic effects when combined with the standard chemotherapeutic agent cytarabine, enhancing antitumor activity in both cell lines and zebrafish models of AML.